RTP Mobile Logo

Thursday, February 14, 2019, San Francisco, California, 6:45 PM – 8:45 PM

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Prostate Cancer

Event Details

Location:
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Time:
6:30 PM – 6:45 PM — Registration
6:45 PM – 8:45 PM — Educational Dinner Meeting

Meeting Room:
Yerba Buena Ballroom, Salon 9-15 (Lower B2 Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Faculty:
Emmanuel S Antonarakis, MD
Associate Professor of Oncology and Urology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

A Oliver Sartor, MD
CE and Bernadine Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana

Howard I Scher, MD
D Wayne Calloway Chair in Urologic Oncology
Co-Chair, Center for Mechanism Based Therapy
Head, Biomarker Development Initiative
Member and Attending Physician
Genitourinary Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Cora N Sternberg, MD
Clinical Director, Englander Institute for Precision Medicine
Weill Cornell Medicine
Hematology/Oncology
New York, New York

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2019 Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2019 Genitourinary Cancers Symposium.

Agenda

6:30 PM – 6:45 PM — Registration
6:45 PM – 8:45 PM — Educational Dinner Meeting

MODULE 1: Incorporation of Androgen Receptor Antagonists into the Management of M0 Prostate Cancer (PC) — Dr Smith

  • Pharmacologic and pharmacodynamic similarities and differences among available (eg, apalutamide, enzalutamide) and investigational (eg, darolutamide) androgen receptor antagonists
  • Published findings from the Phase III PROSPER and SPARTAN trials evaluating enzalutamide and apalutamide in patients with nonmetastatic castration-resistant PC (CRPC)
  • FDA approvals of apalutamide and enzalutamide for patients with nonmetastatic CRPC and optimal integration into current clinical algorithms
  • Design, eligibility criteria and key efficacy and safety data from the Phase III ARAMIS trial evaluating darolutamide in patients with high-risk nonmetastatic CRPC

MODULE 2: Management of Metastatic Hormone-Sensitive PC (mHSPC) — Dr Sternberg

  • Long-term efficacy and quality-of-life data associated with the use of docetaxel or abiraterone and prednisone in combination with androgen deprivation therapy (ADT) for men with mHSPC; key clinical and practical factors guiding the selection of docetaxel or abiraterone
  • Recently updated ASCO guideline recommendations regarding the management of newly diagnosed mHSPC
  • Design, eligibility criteria and patient accrual to the Phase III ARCHES study comparing enzalutamide and ADT to ADT alone for patients with mHSPC; radiographic progression-free survival advantage associated with enzalutamide and ADT in the ARCHES study and potential clinical implications
  • Ongoing Phase III trials evaluating approved and investigational antiandrogens (eg, ARASENS, TITAN) in patients with mHSPC
  • Biologic rationale for and design, eligibility criteria and key efficacy and safety endpoints being evaluated in the ongoing Phase III PEACE-1 trial of ADT with docetaxel with or without local radiation therapy with or without abiraterone/prednisone for mHSPC

MODULE 3: Current and Future Management of Metastatic CRPC (mCRPC) — Dr Scher

  • Impact of earlier use of chemotherapy and secondary hormonal therapy for M0 or metastatic hormone-sensitive PC on the selection and sequencing of systemic treatment for mCRPC
  • Published research findings documenting the correlation between the presence of androgen receptor splice variant 7 (AR-V7) and outcomes with secondary hormonal therapy and chemotherapy; current clinical role of AR-V7 in patients with mCRPC
  • Incidence of microsatellite instability/mismatch repair deficiency (MSI/MMR) in patients with mCRPC; indications for MSI/MMR testing and current role of immune checkpoint inhibitors in patients with and without MSI-high/MMR-deficient disease
  • Other promising agents and strategies under investigation in mCRPC

MODULE 4: Biologic Rationale for and Ongoing Evaluation of PARP Inhibitors in the Management of mPC — Dr Antonarakis

  • Spectrum and frequency of somatic and germline DNA repair mutations in PC; indications for and practical implementation of genetic testing
  • Biologic rationale for and proposed mechanisms of antitumor activity of PARP inhibitors in mPC
  • Available clinical trial data with the use of olaparib and rucaparib in patients with progressive mCRPC; FDA breakthrough therapy designations and ongoing Phase III trials with these agents
  • Biologic rationale for and ongoing evaluation of PARP inhibitors in combination with other anticancer therapies (eg, secondary hormonal agents, immune checkpoint inhibitors)

MODULE 5: Bone-Targeted Therapies and Other Emerging Radiopharmaceuticals — Dr Sartor

  • Patient selection for radium-223 and ongoing trials evaluating the optimal dose and schedule
  • Design, eligibility criteria and key efficacy and safety data from the Phase III ERA 223 trial evaluating radium-223 in combination with abiraterone and prednisone for chemotherapy-naïve mCRPC; implications for current and future research and clinical management
  • Biologic rationale for and ongoing evaluation of radium-223 in combination with other anticancer therapies
  • Early activity and safety results and ongoing evaluation of other novel radiopharmaceuticals (eg, 225Ac-PSMA-617, 177Lu-PSMA-617)

CE Information

Target Audience:
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer (PC).

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Appraise recent data on diagnostic and therapeutic advances in PC, and integrate this information, as appropriate, into current clinical care.
  • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic PC, and consider this information in the discussion of nonresearch treatment options for these patients.
  • Explore available data on the use of cytotoxic and secondary hormonal therapy in the setting of hormone-sensitive metastatic PC to effectively design treatment plans for appropriate individuals.
  • Apply evidence-based research findings in the determination of best-practice selection and sequencing of available local and systemic treatment modalities for patients with metastatic PC.
  • Describe the rationale for testing patients with metastatic PC for BRCA1/2 or ATM mutations, and advise individuals found to harbor these genetic abnormalities about participation in clinical trials evaluating the role of a PARP inhibitor.
  • Recall the design of ongoing research studies evaluating other novel agents and strategies for PC, and counsel appropriate patients about availability and participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
Penn State College of Medicine designates this live activity for a maximum of 2 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
It is the policy of Research To Practice and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Penn State College of Medicine will ensure that any conflicts of interest are resolved before the educational activity occurs. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, a Pfizer Company, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC and Sanofi Genzyme.

Location

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room:
Yerba Buena Ballroom, Salon 9-15 (Lower B2 Level)

Directions:
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center, where the 2019 Genitourinary Cancers Symposium is taking place.

 

Registration

This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.